Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Sorafenib remains the only approved molecular targeted agent for hepatocellular carcinoma (HCC); however, reliable biomarkers that predict its efficacy are still lacking. The aim of this study was to explore whether cancer stem cell (CSC) markers have a predictive role with regard to the sorafenib response in HCC patients. Methods: We enrolled 47 patients with HCC for whom tumor samples obtained before starting sorafenib treatment were available. RNA was extracted from formalin-fixed, paraffin-embedded samples, and real-time polymerase chain reaction was used to quantify mRNA expression of the CSC genes EpCAM , CD13, CK8, CD24, CD44, CD90, CD133, SALL4, ALDH1A1, ALB , and AFP . Results: Of 47 patients, 14.9% and 74.5% had vascular invasion and extrahepatic spread, respectively. Patients with low CD133 expression tended to have longer progression-free survival (PFS) than those with high CD133 expression (5.5 months vs 4.0 months), although without statistical significance. The expression levels of other markers were not associated with PFS. When examining markers in combination, patients with high CD133 and CD90 expression had shorter PFS rates than those with low expression (2.7 months vs 5.5 months; p=0.04). Patients with low CD133 and EpCAM expression demonstrated better PFS than those with high expression (7.0 months vs 4.2 months; p=0.04). Multivariable analysis indicated that an Eastern Cooperative Oncology Group performance status score of 1 and high CD133/CD90 expression were significantly associated with shorter PFS. Conclusions: Overexpression of the CSC markers CD133 and CD90 in HCC was associated with poorer response to sorafenib. These two genes may serve as predictive biomarkers for sorafenib therapy.
Abstract
Background/Aims: Sorafenib remains the only approved molecular targeted agent for hepatocellular carcinoma (HCC); however, reliable biomarkers that predict its efficacy are still lacking. The aim of this study was to explore whether cancer stem cell (CSC) markers have a predictive role with regard to the sorafenib response in HCC patients. Methods: We enrolled 47 patients with HCC for whom tumor samples obtained before starting sorafenib treatment were available. RNA was extracted from formalin-fixed, paraffin-embedded samples, and real-time polymerase chain reaction was used to quantify mRNA expression of the CSC genes EpCAM , CD13, CK8, CD24, CD44, CD90, CD133, SALL4, ALDH1A1, ALB , and AFP . Results: Of 47 patients, 14.9% and 74.5% had vascular invasion and extrahepatic spread, respectively. Patients with low CD133 expression tended to have longer progression-free survival (PFS) than those with high CD133 expression (5.5 months vs 4.0 months), although without statistical significance. The expression levels of other markers were not associated with PFS. When examining markers in combination, patients with high CD133 and CD90 expression had shorter PFS rates than those with low expression (2.7 months vs 5.5 months; p=0.04). Patients with low CD133 and EpCAM expression demonstrated better PFS than those with high expression (7.0 months vs 4.2 months; p=0.04). Multivariable analysis indicated that an Eastern Cooperative Oncology Group performance status score of 1 and high CD133/CD90 expression were significantly associated with shorter PFS. Conclusions: Overexpression of the CSC markers CD133 and CD90 in HCC was associated with poorer response to sorafenib. These two genes may serve as predictive biomarkers for sorafenib therapy.
참고문헌 (45)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebocontrolled trial", Lancet Oncol, 10, pp.25~34 (2009)
- Llovet JM, "Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma", Clin Cancer Res, 18, pp.2290~2300 (2012)
- Kuzuya T, "Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma", Oncology, 81, pp.251~258 (2011)
- Ueshima K, "Des-gamma-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma", Dig Dis, 29, pp.321~325 (2011)
- Kudo M, "Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma : a single-center experience", Dig Dis, 30, pp.609~616 (2012)
- Estfan B, "Sorafenib in advanced hepatocellular carcinoma : hypertension as a potential surrogate marker for efficacy", Am J Clin Oncol, 36, pp.319~324 (2013)
- Koschny R, "Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma", Oncology, 84, pp.6~13 (2013)
- Bettinger D, "Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma", Hepatology, 56, pp.789~790 (2012)
- Clevers H, "The cancer stem cell : premises, promises and challenges", Nat Med, 17, pp.313~319 (2011)
- O’Connor ML, "Cancer stem cells : a contentious hypothesis now moving forward", Cancer Lett, 344, pp.180~187 (2014)
- Clarke MF, "Cancer stem cells: perspectives on current status and future directions: AACR Workshop on cancer stem cells", Cancer Res, 66, pp.9339~9344 (2006)
- Cheng Z, "Characteristics of liver cancer stem cells and clinical correlations", Cancer Lett, 379, pp.230~238 (2016)
- Fernando J, "A mesenchymallike phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells", Int J Cancer, 136, pp.E161~E172 (2015)
- Hagiwara S, "Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma", Br J Cancer, 106, pp.1997~2003 (2012)
- 한국 간 암 스터디그룹, "2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma", Gut and Liver, 9(3), pp.267~317 (2015), 거트앤리버 소화기연관학회협의회
- Yu SJ, "A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world : 2010-2016", Clin Mol Hepatol, 22, pp.7~17 (2016)
- Korean Liver Cancer Study Group, "Practice guidelines for management of hepatocellular carcinoma 2009", Korean J Hepatol, 15, pp.391~423 (2009)
- Lencioni R, "Modified RECIST(mRECIST)assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
- Zhao J, "Cancer stem cells and chemoresistance : the smartest survives the raid", Pharmacol Ther, 160, pp.145~158 (2016)
- Gottesman MM, "Multidrug resistance in cancer : role of ATP-dependent transporters", Nat Rev Cancer, 2, pp.48~58 (2002)
- Ma S, "Biology and clinical implications of CD133(+)liver cancer stem cells", Exp Cell Res, 319, pp.126~132 (2013)
- Singh SK, "Identification of human brain tumour initiating cells", Nature, 432, pp.396~401 (2004)
- Ricci-Vitiani L, "Identification and expansion of human colon-cancer-initiating cells", Nature, 445, pp.111~115 (2007)
- Tirino V, "The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer", Eur J Cardiothorac Surg, 36, pp.446~453 (2009)
- Qiu HO, "Identification and characterization of CD133(pos)subpopulation cells from a human laryngeal cancer cell line", Med Sci Monit, 22, pp.1146~1151 (2016)
- Ma S, "Identification and characterization of tumorigenic liver cancer stem", progenitor cells, 2007, pp.132, 2542~2556
- Song W, "Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma", Int J Clin Pract, 62, pp.1212~1218 (2008)
- Ma S, "miR-130b Promotes CD133(+)liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1", Cell Stem Cell, 7, pp.694~707 (2010)
- Liu G, "Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma", Mol Cancer, 5, pp.67~ (2006)
- Liu YP, "Cisplatin selects for multidrugresistant CD133+ cells in lung adenocarcinoma by activating Notch signaling", Cancer Res, 73, pp.406~416 (2013)
- Lee MR, "Chemoresistance of CD133(+)colon cancer may be related with increased survivin expression", Biochem Biophys Res Commun, 463, pp.229~234 (2015)
- Ma S, "CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt", PKB survival pathway, 2008, pp.27, 1749~1758
- Piao LS, "CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma", Cancer Lett, 315, pp.129~137 (2012)
- Rege TA, "Thy-1 as a regulator of cell-cell and cellmatrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis", FASEB J, 20, pp.1045~1054 (2006)
- Kumar A, "Multiple roles of CD90 in cancer", Tumour Biol, 37, pp.11611~11622 (2016)
- Tang KH, "A CD90(+)tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer", Cancer Res, 73, pp.2322~2332 (2013)
- Zhu GC, "CD90 is upregulated in gastric cancer tissues and inhibits gastric cancer cell apoptosis by modulating the expression level of SPARC protein", Oncol Rep, 34, pp.2497~2506 (2015)
- He J, "CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays", Mol Cell Proteomics, 11, pp.M111.01074~ (2012)
- Liu R, "Association between expression of cancer stem cell markers and poor differentiation of hepatocellular carcinoma: a meta-analysis (PRISMA)", Medicine (Baltimore), 94, pp.e1306~ (2015)
- Zhao RC, "The prognostic value of combination of CD90 and OCT4 for hepatocellular carcinoma after curative resection", Neoplasma, 63, pp.288~298 (2016)
- Guo Z, "Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma", World J Gastroenterol, 20, pp.2098~2106 (2014)
- Sukowati CH, "The expression of CD90", Thy-1 in hepatocellular carcinoma : an in vivo and in vitro study, 2013, pp.8, e76830~
- Jia Q, "Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+)liver cancer stem cells", Cell Reprogram, 15, pp.143~150 (2013)
- Finn RS, "The role of liver biopsy in hepatocellular carcinoma", Gastroenterol Hepatol(N Y), 12, pp.628~630 (2016)